Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Invitrogen collaboration will ‘enhance understanding’ of RNAs

Invitrogen collaboration will ‘enhance understanding’ of RNAs

12th November 2007

Invitrogen has announced a licensing agreement with Natural Selection to make new microRNA sequences available to researchers.

According to the provider of essential life science technologies for research, production and diagnostics, the agreement will enable the provision of the most comprehensive human and mouse microRNA arrays on the market.

With the microRNA sequences submitted to the on-line database of the Sanger Institute, a leading biomedical research charity, the agreement is intended to lead to a significant increase in human and mouse microRNA content on the market.

"For the first time, scientists will be able to investigate the role of many novel and previously unknown microRNAs using Invitrogen’s microRNA arrays with Natural Selection content," confirmed Amy Butler, Invitrogen’s vice-president of gene expression profiling.

"By combining these new sequences with the latest Sanger 10.0 content, we are greatly expanding the potential for discovery of novel microRNA biomarkers for disease and development," she added.

A spokesperson for Natural Selection pointed out that the new tools will "significantly enhance" the research community’s understanding of the role of small RNAs in biological processes, with this advance particularly important in the areas of cancer and stem cell research where microRNAs have been found to play a critical role. ADNFCR-1050-ID-18351078-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.